Description
Syndopa CR 125 mg is a controlled-release tablet combining Levodopa (100 mg) and Carbidopa (25 mg), manufactured by Sun Pharmaceutical Industries Ltd. This formulation is specifically designed for the treatment of Parkinson’s disease and related movement disorders. Levodopa serves as a precursor to dopamine, a neurotransmitter deficient in the brains of Parkinson’s patients, and crosses the blood-brain barrier to be converted into dopamine. Carbidopa inhibits the peripheral conversion of Levodopa into dopamine, ensuring more Levodopa reaches the brain and reducing side effects like nausea. The "CR" (Controlled Release) designation indicates that the tablet releases its active ingredients gradually over time, providing a more consistent therapeutic effect and reducing the frequency of dosing compared to immediate-release formulations. This controlled-release mechanism helps in managing motor fluctuations and "off" periods commonly experienced by patients with Parkinson’s disease.
.jpg)
Change Language